KemPharm, Inc.

Good day and thank you for standing by. Welcome to the Camp Farm third quarter 2021 results conference call. At this time, all participants are in a listen-only mode. After the speaker's presentation, there will be a question and answer session. Please be advised that today's conference is being recorded. If you require any further assistance, please press star zero. I would now like to hand the conference over to your first speaker today, Jason Randall with Tiburon Strategic Advisors. Sir, please go ahead.

Good afternoon and thank you for joining our call today to discuss ChemPharm's third quarter 2021 financial and corporate results. Before we begin, I would like to remind our listeners that remarks made during this call may contain forward-looking statements that involve risks and uncertainties and are subject to changes at any time, including but not limited to statements about ChemPharm's expectations regarding future operating results. Forward-looking statements are made pursuant to the safe harbor provisions of the federal securities laws and represent management's current expectations. Actual results may differ materially. ChemPharm disclaims any obligation to update or revise its forward-looking statements except as required by law. More complete information regarding forward-looking statements, risks, and uncertainties can be found in ChemPharm's filings with the SEC, which are available on ChemPharm's website under the Investor Relations section. Speaking on today's call will be Travis Mikkel, ChemPharm's president and CEO, and LaDwayne Clifton, CFO. Following the remarks will be a question and answer session, which will include responses to questions that were submitted during the past week. With that, it is my pleasure to introduce Travis.

Thanks, Jason, and thanks, everyone, for joining us on our call today. The third quarter was certainly a big and transformational quarter for the company. Our biggest news, of course, was the launch of Astaris And as most of you are certainly very focused on the launch of the product and the near term here, while we can't give a lot of details based on our agreement with Coriam, we are certainly excited to share with you what has been passed along is that within the first 100 days into the launch, they now have access to over 50 million lives that are covered by both commercial and Medicaid insurance. And that's certainly, in my experience and what I have seen, has been a tremendous win in the early days of the launch. That's certainly a remarkable achievement in such a short amount of time, and it certainly speaks to the Quorium's team's deep experience in the managed market space. Another highlight of the – really a recent highlight and kind of a look forward, we have the SDX trial that got underway in the Q3 period. as well as continues to proceed, expected still to have data available before year-end for that particular trial. From that data, we will provide more detail on the clinical development path for STX or STX-related products and indications. Again, another great quarter financially. LeDwayne will report the details there. But certainly revenue based on our consulting fees continues as well as our continued small spend until we have the resources and the budget available for our development programs. And then last but not least, as many of you have already seen in the press release, we continue to advance strategically forward as a company and with our board. Welcome today with me and LeDwayne, Rich Pascoe. He has joined today as our executive chairman, helpful here in the office as well as with the board. He's here to help guide our organization in the future. He's joined us here on this call, so Rich, I would turn it over to you if you want to say a few words.